Triomics raises $22M for oncology AI platform

Triomics has secured $22 million in Series B funding to advance its AI-powered platform designed for oncology. The platform aims to automate data-intensive tasks for cancer centers, including clinical trial matching and patient record summarization. This funding, led by Battery Ventures, will help Triomics address the growing complexity of patient histories and reduce administrative burdens on healthcare staff. By training models specifically on oncology data, Triomics offers specialized solutions that differentiate it from generic AI tools and competitors like Abridge and Nuance. The company has experienced significant growth, with its enterprise customer base quadrupling and annualized recurring revenue increasing tenfold over the past year.